BCM
TVTX icon

Bridgeway Capital Management’s Travere Therapeutics TVTX Stock Holding History

Bridgeway Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-33,064
Closed -$670K – 1494
2015
Q3 		$670K Sell
33,064
-28,836
-47% -$854K 0.01% 895
2015
Q2 		$2.05M Sell
61,900
-6,000
-9% -$164K 0.04% 504
2015
Q1 		$1.63M Hold
67,900
– – 0.03% 593
2014
Q4 		$831K Buy
67,900
+19,350
+40% +$200K 0.02% 841
2014
Q3 		$438K Buy
+48,550
New +$571K 0.01% 1139

Other funds holding TVTX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bridgeway Capital Management's TVTX Position: Q4 2015 in Review

Bridgeway Capital Management sold out of Travere Therapeutics (TVTX) in Q4 2015, closing a stake of 33,064 shares — an estimated $670K sold.

Bridgeway Capital Management first reported a position in TVTX in Q3 2014 and held it in 5 quarters. The position peaked at $2.05M in Q2 2015. 116 funds tracked by Wall St. Rank hold TVTX as of Q4 2015.

  • Bridgeway Capital Management reported no remaining Travere Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Bridgeway Capital Management sold 33,064 Travere Therapeutics shares in Q4 2015, an estimated $670K.
  • Bridgeway Capital Management first reported a position in Travere Therapeutics in Q3 2014 and held it in 5 quarters.
  • Bridgeway Capital Management's Travere Therapeutics position peaked at $2.05M in Q2 2015.
  • 116 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2015.

Based on Bridgeway Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.